Definition
Telemedicine is the use of telecommunications technology to deliver clinical healthcare services — including diagnosis, treatment, and patient monitoring — at a distance, enabling providers to evaluate and treat patients without an in-person encounter.
Comprehensive Definition
Telemedicine refers specifically to the remote delivery of clinical medical services using telecommunications technology. Unlike the broader term "telehealth," telemedicine is limited to clinical care — the diagnosis, treatment, and management of patients by licensed healthcare providers. It encompasses a range of modalities including synchronous (real-time) audio/video visits, asynchronous (store-and-forward) consultations, and remote patient monitoring (RPM) programs that transmit physiologic data from patients to clinicians.
The four primary modalities of telemedicine are: (1) synchronous telemedicine, which involves real-time audio and video communication between a patient and provider; (2) asynchronous telemedicine (store-and-forward), in which patient data, images, or information is collected and transmitted to a provider for review at a later time; (3) remote patient monitoring (RPM), in which physiologic data is collected from patients in their home environment and transmitted electronically to a provider for review and management; and (4) mobile health (mHealth), which encompasses the use of mobile devices and applications to support health and wellness.
Telemedicine is distinct from telehealth in that telehealth is a broader umbrella term that includes not only clinical services (telemedicine) but also non-clinical services such as health education, administrative functions, and public health activities. The distinction matters for regulatory and reimbursement purposes — Medicare and Medicaid coverage rules, state licensure requirements, and prescribing regulations often apply specifically to telemedicine (clinical services) rather than to telehealth broadly.
The legal and regulatory framework for telemedicine is complex and multi-layered. At the federal level, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 restricts the prescribing of controlled substances via telemedicine without a prior in-person evaluation. The DEA has issued rules implementing the Ryan Haight Act and has proposed a framework for special registration that would allow certain telemedicine providers to prescribe controlled substances without a prior in-person visit. Medicare coverage for telemedicine services is governed by Section 1834(m) of the Social Security Act and implementing regulations at 42 CFR Part 410.
State licensure requirements add another layer of complexity. In most states, a provider must be licensed in the state where the patient is located at the time of the telemedicine encounter — not the state where the provider is physically located. The Interstate Medical Licensure Compact (IMLC) facilitates multi-state licensure for physicians, and similar compacts exist for nurses and other providers. Operators launching telemedicine practices must carefully map their patient population to ensure that all treating providers hold appropriate licensure in the relevant states.
Why It Matters
Telemedicine has fundamentally changed the economics and geography of healthcare delivery. For patients, it eliminates barriers of distance, transportation, and time — enabling access to specialist care that would otherwise require hours of travel, or primary care for patients in rural and underserved communities. For providers and healthcare entrepreneurs, telemedicine opens new revenue streams, enables practice expansion across state lines, and supports the delivery of high-volume, low-acuity care at significantly lower overhead than brick-and-mortar facilities.
For healthcare operators, understanding the regulatory framework governing telemedicine is not optional — it is a prerequisite for building a legally compliant and financially sustainable practice. The intersection of state licensure requirements, federal prescribing rules (particularly the Ryan Haight Act for controlled substances), and Medicare/Medicaid coverage rules creates a compliance matrix that must be carefully navigated. Operators who launch telemedicine practices without understanding these requirements expose themselves to significant legal, regulatory, and financial risk.
The COVID-19 public health emergency (PHE) dramatically expanded telemedicine coverage and relaxed many regulatory restrictions — including DEA prescribing rules and Medicare originating site requirements. Many of these flexibilities have been extended beyond the PHE, but the regulatory landscape continues to evolve. Operators must stay current with federal and state telemedicine regulations to ensure ongoing compliance.
Historical Background
Telemedicine has existed in various forms since the early 20th century, when physicians used telephone consultations to advise patients in remote locations. The modern era of telemedicine began in the 1960s and 1970s, when NASA and academic medical centers began experimenting with video-based consultations for astronauts and remote communities. The University of Nebraska conducted some of the earliest formal telemedicine programs in the 1950s and 1960s.
The passage of the Balanced Budget Act of 1997 marked the first time Medicare provided reimbursement for telemedicine services, though coverage was initially limited to rural areas and specific service types. The HITECH Act of 2009 and the Affordable Care Act of 2010 further expanded the infrastructure and policy framework for telemedicine. The COVID-19 PHE, declared in March 2020, triggered the most significant expansion of telemedicine coverage in history — CMS waived originating site restrictions, allowed audio-only visits, and permitted prescribing of controlled substances via telemedicine without a prior in-person evaluation.
Federal Regulations
Medicare telemedicine coverage is governed by Section 1834(m) of the Social Security Act and implementing regulations at 42 CFR § 410.78. Medicare covers telemedicine services for beneficiaries in rural health professional shortage areas (HPSAs) and non-metropolitan statistical areas (non-MSAs), subject to originating site requirements — though many of these restrictions were waived during the COVID-19 PHE and some waivers have been extended.
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. § 829(e)) prohibits the prescribing of controlled substances via the internet (including telemedicine) without a prior in-person medical evaluation, subject to limited exceptions. The DEA has proposed a Special Registration framework (88 Fed. Reg. 12875, March 1, 2023) that would allow registered telemedicine providers to prescribe certain controlled substances without a prior in-person visit, but final rules have not yet been issued as of mid-2025.
The FTC Act and state consumer protection laws apply to telemedicine marketing and advertising. HIPAA applies to all telemedicine providers that are covered entities, requiring HIPAA-compliant platforms and Business Associate Agreements with technology vendors. The 21st Century Cures Act information blocking rules (45 CFR Part 171) apply to telemedicine providers that are healthcare providers under the ONC definition.
State Considerations
State licensure is the most significant state-level consideration for telemedicine operators. In most states, a provider must hold an active, unrestricted license in the state where the patient is physically located at the time of the telemedicine encounter. The Interstate Medical Licensure Compact (IMLC) allows eligible physicians to obtain licenses in multiple member states through a streamlined process. Similar compacts exist for advanced practice registered nurses (APRN Compact), physician assistants (PA Compact), and other provider types.
Many states have enacted telemedicine-specific practice standards that govern the establishment of a valid provider-patient relationship via telemedicine, prescribing standards, and documentation requirements. Some states require an initial in-person evaluation before a provider-patient relationship can be established via telemedicine; others permit the relationship to be established via telemedicine alone. State medical boards are the primary enforcement authority for telemedicine practice standards.
State insurance coverage mandates for telemedicine vary significantly. As of 2025, the majority of states have enacted telemedicine coverage parity laws requiring commercial insurers to cover telemedicine services on the same basis as in-person services. However, the scope of these mandates varies — some apply only to synchronous video visits, while others include asynchronous and audio-only services. Medicaid telemedicine coverage also varies by state, with each state's Medicaid program setting its own coverage rules subject to CMS approval.
Common Mistakes
- Failing to verify that all treating providers hold active, unrestricted licenses in every state where patients are located — not just the state where the provider or practice is based.
- Prescribing controlled substances via telemedicine without understanding the Ryan Haight Act requirements and applicable DEA rules, exposing the practice to federal criminal liability.
- Using non-HIPAA-compliant video platforms (e.g., standard FaceTime, Zoom without a BAA) for telemedicine encounters, creating HIPAA Privacy and Security Rule violations.
- Failing to establish a valid provider-patient relationship in accordance with the telemedicine practice standards of the patient's state before prescribing or treating.
- Assuming that COVID-19 PHE telemedicine flexibilities are permanent — many waivers have expired or are subject to change, and operators must monitor regulatory updates.
- Not documenting telemedicine encounters with the same rigor as in-person visits — state medical boards and payers require documentation that supports the services billed.
Operator Insight
When I work with clients launching telemedicine practices, the first thing I tell them is that telemedicine is not a technology problem — it is a regulatory and operational problem that happens to use technology. The platform is the easy part. The hard part is building a compliance infrastructure that covers state licensure, prescribing rules, HIPAA, and payer credentialing across every state where you intend to see patients. The Ryan Haight Act is the issue I see most often misunderstood by telemedicine entrepreneurs, particularly those building practices around controlled substance prescribing — weight loss (stimulants), mental health (benzodiazepines, stimulants for ADHD), and pain management. The DEA's proposed Special Registration framework has been in development for years, and until final rules are issued, operators must comply with the existing Ryan Haight requirements or qualify for one of the narrow statutory exceptions. Getting this wrong is not a compliance issue — it is a federal criminal issue. My advice to operators is to build your telemedicine practice around a clear clinical scope, map your patient population to the states where you will operate, and build your licensure and compliance infrastructure before you see your first patient. The cost of doing this right upfront is a fraction of the cost of a DEA investigation, a state medical board complaint, or a Medicare audit.
— AJ Pakpour, Healthcare Practice Startup & Strategy Expert
In Practice
A direct-to-consumer telemedicine startup launches a platform for weight management, offering GLP-1 prescriptions via synchronous video visits. Before launch, the medical director maps the target patient population to the top 10 states by volume, verifies that all treating providers hold active licenses in those states, and implements a HIPAA-compliant video platform with a signed BAA. The practice establishes a provider-patient relationship policy consistent with the telemedicine practice standards of each state, and implements a controlled substance prescribing policy that complies with the Ryan Haight Act — requiring an initial synchronous video visit before any prescription is issued. A hospital system expands its specialty care access by launching a store-and-forward dermatology telemedicine program. Patients at rural primary care clinics submit photographs of skin lesions through a secure patient portal; dermatologists at the academic medical center review the images asynchronously and provide consultation reports within 48 hours. The program is structured to comply with Medicare's store-and-forward telemedicine coverage rules for federal telemedicine demonstration programs, and all dermatologists hold licenses in the states where the originating site clinics are located.
Frequently Asked Questions
References
Further Reading
Turn Knowledge Into Action
Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.
Book a Strategy Session